Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

4.180 +0.270 (+6.91%)
Streaming Delayed Price Updated: 2:11 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
$50M Bet On Coinbase Global? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Thursday, there were a few notable insider trades. 
Via Benzinga
The Latest Analyst Ratings for 4D Molecular Therapeutics
Via Benzinga
SVB Securities Maintains Market Perform Rating for 4D Molecular Therapeutics: Here's What You Need To Know
Via Benzinga
Expert Ratings for 4D Molecular Therapeutics
Via Benzinga
Analyst Ratings for 4D Molecular Therapeutics
Via Benzinga
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Underwriters’ full exercise of option brings gross proceeds to $138.0 million 
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
What's Going On With 4D Molecular Therapeutics Stock Today
4D Molecular Therapeutics (NASDAQ: FDMT) shares are trading lower after the company released interim clinical data from the Phase 1 Dose Exploration stage of the 4D-150 Phase 1/2 PRISM trial for wet... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its... 
Via Benzinga
Dow Surges 100 Points; Meta Platforms Reports Upbeat Results
U.S. stocks traded higher this morning, with the Dow Jones gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.38% to 33,429.66 while the NASDAQ rose 0.88%... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks Sitting in the Sweet Spot
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. 
Via InvestorPlace
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study
Via Benzinga
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS